Business Description
Olema Pharmaceuticals inc
NAICS : 325412
SIC : 2834
Description
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 78.66 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -127.2 | |||||
| 3-Year EPS without NRI Growth Rate | -80.9 | |||||
| 3-Year FCF Growth Rate | -104.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.64 | |||||
| 9-Day RSI | 55 | |||||
| 14-Day RSI | 62.42 | |||||
| 6-1 Month Momentum % | -50.75 | |||||
| 12-1 Month Momentum % | -55.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.93 | |||||
| Quick Ratio | 17.93 | |||||
| Cash Ratio | 17.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -41.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -38.42 | |||||
| ROA % | -36.7 | |||||
| ROIC % | -1101.89 | |||||
| ROC (Joel Greenblatt) % | -2696.68 | |||||
| ROCE % | -38.52 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.84 | |||||
| Price-to-Tangible-Book | 0.84 | |||||
| EV-to-EBIT | 0.35 | |||||
| EV-to-EBITDA | 0.35 | |||||
| EV-to-FCF | 0.44 | |||||
| Price-to-Net-Current-Asset-Value | 0.86 | |||||
| Price-to-Net-Cash | 0.87 | |||||
| Earnings Yield (Greenblatt) % | 285.71 |
